How an Unproven Alzheimer’s Drug Got Approved


By BY PAM BELLUCK, SHEILA KAPLAN AND REBECCA ROBBINS
Health
https://ift.tt/2V2fsC8
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
New York Times
Aduhelm (Drug), Alzheimer's Disease, Drugs (Pharmaceuticals), Labeling and Labels (Product), Clinical Trials, Elderly, Science and Technology, Regulation and Deregulation of Industry, Research, Brain, your-feed-science, your-feed-healthcare
July 20, 2021 at 02:12AM

Popular posts from this blog

Why Do We Think It's Okay to Invade Strangers' Privacy?

Image
Why Do We Think It's Okay to Invade Strangers' Privacy? Last week, Rosey Blair, a writer and self-described “drama queen deep in the heart of Texas,” boarded a plane and began a Twitter thread that changed her life  —  and the lives of the two people sitting in front of her. July 14, 2018 at 10:13PM Continue: https://ift.tt/2mfppaC
Read more

Why American Spies Worry When Trump Meets Putin

Image
Why American Spies Worry When Trump Meets Putin It was going to be Donald Trump’s "easiest" meeting, at least according to Trump himself. After a week of tense exchanges with allies in Brussels and then the U.K., the U.S president would head to Helsinki for his first formal summit with Russian President Vladimir Putin. Then on Friday, right as the president was settling down to tea with the Queen, the indictments came. July 14, 2018 at 03:43PM Continue: https://ift.tt/2L6tz2D
Read more